Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uremic vasculopathy.

Sharon M Moe1

  • 1Indiana University School of Medicine, Indianapolis, IN 46260, USA. smoe@iupui.edu

Seminars in Nephrology
|October 19, 2004
PubMed
Summary
This summary is machine-generated.

Uremic vascular calcification in end-stage renal disease (ESRD) is an active, cell-driven process. Uremic serum promotes vascular smooth muscle cell mineralization, suggesting a pathway for therapeutic intervention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related differences in the skeletal phenotype of Brown Norway rats induced to develop chronic kidney disease.

Bone·2026
Same author

Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.

Bone·2026
Same author

Radiomics identifies distinct cortical bone texture alterations in patients with CKD using HR-pQCT.

Bone research·2026
Same author

Determining Physical Function Measures for Estimating VO<sub>2</sub>Peak in Patients Receiving Hemodialysis.

Kidney medicine·2026
Same author

A Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis.

Kidney360·2025
Same author

Reference Data and Predictors of HR-pQCT-Derived Muscle Density and Its Prediction of Physical Performance.

Journal of cachexia, sarcopenia and muscle·2025
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Area of Science:

  • Vascular Biology
  • Nephrology
  • Bone Biology

Background:

  • Uremic vascular calcification is a significant complication in end-stage renal disease (ESRD) patients.
  • Traditionally viewed as passive precipitation, recent evidence suggests it's an active, cell-mediated process.
  • This process shares similarities with osteogenesis (bone formation).

Purpose of the Study:

  • To investigate the cellular and molecular mechanisms underlying uremic vascular calcification.
  • To identify key bone-associated proteins and transcription factors involved in this process.
  • To explore the role of the uremic milieu in vascular smooth muscle cell mineralization.

Main Methods:

  • Histologic analysis of inferior epigastric arteries from ESRD patients.

Related Experiment Videos

  • Assessment of bone-associated proteins (osteopontin, bone sialoprotein, alkaline phosphatase, type I collagen) and core-binding factor alpha-1 (Cbfa1).
  • In vitro experiments using cultured vascular smooth muscle cells exposed to uremic serum.

    • Main Results:

    • Increased expression of osteopontin, bone sialoprotein, alkaline phosphatase, type I collagen, and Cbfa1 was observed in arteries from ESRD patients.
    • Uremic serum exposure in vitro upregulated osteopontin and Cbfa1 expression in vascular smooth muscle cells.
    • Uremic serum accelerated the mineralization of cultured vascular smooth muscle cells.

    Conclusions:

    • Uremic vascular calcification is an active, cell-mediated process driven by the uremic environment.
    • Vascular smooth muscle cells may undergo dedifferentiation and subsequent mineralization in the uremic milieu.
    • Further research into the pathophysiology is crucial for developing therapeutic strategies for ESRD patients.